Newsletter

www.DailyPennyStocks.com does its best to bring you accurate information but errors may and sometimes do occur. Always do your own research before trading. DailyPennyStocks.com is not a licensed financial advisor.  This is a paid marketing newsletter which will state compensation, if any, for the specific company being marketed in the disclaimer at the end of this message.

My Super Hot “POWER” Play is ENDV - Endonovo Therapeutics 

About ENDV:

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off the-shelf, cell-free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases utilizing their bio-electromagnetic platform.

http://endonovo.com/

This is an ultra-high tech play!

And not just high-tech, but high-tech healthcare.

ENDV is a biotechnology company developing non-invasive, bio-electromagnetic products with anti-inflammatory properties designed to promote regeneration in damaged tissue and organs in animals and humans.

This is really incredible, their website says that the basis for Endonovo’s Time-Varying Electromagnetic Field (TVEMF) technology was created at NASA in conjunction with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long term manned missions in outer space.

The original concept of TVEMF was developed when NASA realized that cellular growth increased as the space shuttle crossed the earth’s magnetic poles. It took over eight years to define and develop a device that produced the same effect. This magnetic field device (TVEMF) was originally designed to enhance cellular expansion (growth) in NASA’s rotating wall bioreactor. After numerous experimental studies, the results were so significant with the bioreactor that a prototype was designed for use directly on the human body. 

We're talking about revolutionary technology here!

Just look at one of ENDV's latest news releases:

http://finance.yahoo.com/news/endonovo-therapeutics-targets-non-invasive-130000919.html

LOS ANGELES, April 8, 2015 /PRNewswire/-- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a biotechnology company developing non-invasive, bio-electromagnetic products with anti-inflammatory properties designed to promote regeneration in damaged tissue and organs in animals and humans, today announced  its intention to begin pre-clinical testing of its electroceutical technology to treat and reverse acute and chronic inflammatory liver pathologies. This includes the conditions that cause nonalcoholic steatohepatitis (NASH) and human cirrhotic liver disease.

The American Liver Foundation estimates that up to 30% of the U.S. population is affected by non-alcoholic fatty liver diseases, including NASH and other obesity related liver ailments.

NASH is liver inflammation and cellular damage caused by a buildup of fat in the liver.  NASH occurs in people who drink little or no alcohol, especially people who are middle-aged and overweight or obese. Approximately 20% of NASH cases result in scarring of the liver and cirrhosis if untreated, with the most acute cases often requiring liver transplantation. There are no approved therapies for the treatment of NASH and there are few pharmaceutical therapies nearing approval over the next several years. 

Alan Collier, Chief Executive Officer and Chairman of Endonovo Therapeutic, commented, "We believe Endonovo's proprietary electroceutical technology holds great promise for the treatment of inflammatory conditions of hepatic origin, furthermore addressing NASH and human cirrhotic liver disease with a non-invasive and safe medical device.

"Significant, traditionally pharmaceutically-driven companies are now pivoting towards non-invasive electrotherapies.  As the overall market gains a greater understanding of the physics of biology, the opportunity to develop effective therapies that act at the biophysical level improves.  Endonovo is at the forefront of that opportunity and we foresee the day where virtually untreatable conditions, such as human cirrhotic liver and many other organ diseases, may be treated in such a fashion," concluded Mr. Collier.

Dr. Leonard Makowka, Endovono's Chief Medical Officer, added, "The fact that all biochemical activity is conducted on an electrochemical infrastructure means that using electromagnetic technologies allows us to 'get behind' the biochemistry, thereby avoiding many of the problems with pharmacological therapies and act at the source of the pathology.  For a century we have taken for granted that electromagnetic technologies, like MRI and CAT, are universally applicable and reliable. At Endonovo, we are simply taking this concept — the fundamental and universal validity and reliability of accessing biology at the electromagnetic level — into the therapeutic realm.

Wow!!

ENDV really looks like an exciting company, and that could translate into another hot trade.

Sounds like a smokin' hot one, but remember to trade cautiously and be prepared for anything.

*** Be sure to trade with caution and to verify all information for yourself before trading.  Do your own research and consult with a licensed professional before trading any alert.  You may easily lose your entire investment.  In my personal opinion, the vast majority of companies alerted in this newsletter are too risky for traditional investment, and are discussed here purely from a short-term/daytrading perspective.  All traders should have substantial experience before engaging in the exceptionally risky process that is trading small, micro and nano-cap equities.  Watch out for morning gaps on evening alerts.  ***

We all know that biotech is one of the most volatile and potentially profitable areas of the entire market.

With the kind of tech ENDV says they have, I fully expect traders to express a tremendous interest in this one.

But there is a major catalyst I've been holding out.  Saving the best for last...

Take a look at this:

http://seekingalpha.com/article/3238916-why-endonovo-therapeutics-holds-plenty-of-upside-potential-for-investors

The famous website Seeking Alpha has a new article that's just beginning to make the rounds, that seems to be pushing ENDV HARD!  Seeking alpha articles and other major media coverage could potentially create a frenzy among traders.

ENDV has a high share price of 79 cents, which often attracts the "big money" traders more than the cheap share price plays.  Many prefer a slower trade, but I don't often get one as good as this to alert.  If you're the type who likes higher priced plays, I don't alert them often...so do NOT miss this one!  They tend to be less volatile at higher price points, not quite as "lightning speed." 

Things could get incredibly interesting here, watch out!  

Watch ENDV like a hawk tomorrow and throughout the week...we could see some VERY exciting action.

DPS - Darth Trader

www.dailypennystocks.com

Don’t ever invest based on the info or statements of this newsletter.  Do your own research and consult with a licensed professional before investing, only invest what you are prepared to lose. Any statements and opinions given are amateur and biased and should be treated as such. Past performance does not indicate future performance in any way. The performance of all alerts uncompensated and compensated in no way predict the performance of current and/or upcoming alerts. Check the latest SEC filings before investing, and research other information on the risks of investing in microcap companies at www.sec.gov

 

I would also like to explain to you in simple plain language, instead of overly complex and confusing "disclaimer language" many other newsletters use, exactly how I make money from operating this newsletter.

I am what is known as a STOCK PROMOTER!

That means I get paid to promote public companies.  An "alert" is really a promotion.  Check disclaimers and you will see this is the case at virtually all penny market newsletters.  Many of you assume I make money by getting paid in stock, or something of that nature.  This is not the case.  I make money by getting paid in cash, not stock.  Specifically, wire transfers in USD to my US based bank account.  This is the way most newsletters you read operate, and how they make money too. 

Sometimes I also have issued alerts where I get no payment and do not expect payment, and I just put out the alert at my own discretion.  Typically speaking, most alerts I issue are promotions for which I am paid.  You can always find this info in the disclaimer below.

Furthermore, while I always aggressively state the risks and dangers of trading my alerts, there is a danger that has recently come to my attention.  Various individuals in this "industry" have been accused of issuing press releases and/or general company info for various OTC companies that is false, fraudulent, exaggerated, and so on and so forth.  This means, even if you do very thorough due diligence on a stock, it is always possible that someone involved with the stock may have put false or exaggerated information out there that could be part of your research.  There are only a few cases that I am personally aware of, but how widespread this issue is, is unfortunately unknown.  You should keep this in mind when considering taking any trading action. This is further reason, in my personal opinion, why these OTC companies are not suitable for anything resembling a traditional investment.   (Long term gains are extremely rare)

Here is some information directly from the SEC Website: http://www.sec.gov/investor/pubs/cyberfraud/newsletter.htm

READ IMPORTANT DISCLAIMER

Disclaimer – This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Focus Media.  Any reference to “we” or “our” refers to Focus Media.  Our business model is to be financially compensated to market and promote small public companies.  By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore unqualified to give investment recommendations. Always do your own research and consult with an licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.

We have been compensated fifteen thousand dollars cash via bank deposit/wire to conduct a one day ENDV investor relations advertising campaign by a third party, Meridian Ventures. This compensation is a major conflict of interest in our ability to be unbiased regarding ENDV. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Focus Media’s business model is to receive financial compensation to promote public companies.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.